Expertise in
14
conditions

Dr. Chet W. Hammill

Surgical Oncology
Washington University
660 S Euclid Ave, 
Saint Louis, MO 
Accepting New Patients
Expertise in
14
conditions
Washington University
660 S Euclid Ave, 
Saint Louis, MO 

Overview

Chet Hammill is a Surgical Oncologist practicing medicine in Saint Louis, Missouri.

Dr. Hammill is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Gallbladder Cancer, Gallbladder Adenocarcinoma, Pancreaticoduodenectomy, and Gallbladder Removal.

He is actively involved in clinical research, co-authoring 88 peer reviewed articles and participating in 12 clinical trials. Dr. Hammill is currently accepting new patients.

Specialties

Surgical Oncology

Licenses

Surgery in MO

Hospital Affiliations

Barnes Jewish Hospital
Providence Portland Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

BridgeSpan
  • EPO
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
View 1 Less Insurance Carrier -

Locations

Washington University
660 S Euclid Ave, Saint Louis, MO 63110
Other Locations
Office
4805 NE Glisan St Ste 6N60, Portland, OR 97213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Procedure, Device, Drug
Study Drug: Defactinib
Study Phase: Phase 2
Cabozantinib in High Grade Neuroendocrine Neoplasms
Cabozantinib in High Grade Neuroendocrine Neoplasms
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Procedure, Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Procedure
Study Drugs: BMS-813160, Nivolumab, Gemcitabine, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
Evaluation of the Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Evaluation of the Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Enrollment Status: Terminated
Publish Date: May 06, 2025
Intervention Type: Drug
Study Drug: Pantoprazole
Study Phase: Phase 2
A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Drug, Device
Study Drug: Modified FOLFIRINOX
Study Phase: Phase 3
Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Drug, Device
The Effect of Preoperative and Postoperative Incentive Spirometry in Patients Undergoing Major Abdominal Surgery
The Effect of Preoperative and Postoperative Incentive Spirometry in Patients Undergoing Major Abdominal Surgery
Enrollment Status: Terminated
Publish Date: May 17, 2023
Intervention Type: Device
Study Phase: Not Applicable
Remote Telemonitoring to Improve Prehabilitation and Surgical Outcomes of Patients Undergoing Elective Abdominal Surgery
Remote Telemonitoring to Improve Prehabilitation and Surgical Outcomes of Patients Undergoing Elective Abdominal Surgery
Enrollment Status: Terminated
Publish Date: December 12, 2022
Intervention Type: Other
Study Phase: Not Applicable
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Enrollment Status: Terminated
Publish Date: April 12, 2022
Intervention Type: Other
Study Phase: Not Applicable
Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer
Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drug: MEDI6469
Study Phase: Phase 1
View 9 Less Clinical Trials

88 Total Publications

Mapping Misconceptions in Neuroendocrine Tumor Nomenclature: A Scoping Review of National Database Studies and Clinical Implications.
Mapping Misconceptions in Neuroendocrine Tumor Nomenclature: A Scoping Review of National Database Studies and Clinical Implications.
Journal: Cancers
Published: June 25, 2026
Similar Doctors
Expertise in
5
conditions
Dr. Barbara Z. Dull
Surgical Oncology
Expertise in
5
conditions
Dr. Barbara Z. Dull
Surgical Oncology
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-454-8117
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Barbara Dull is a Surgical Oncologist practicing medicine in Saint Louis, Missouri. Dr. Dull is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Dull is currently accepting new patients.

Expertise in
11
conditions
Dr. Patricia A. Limpert
Surgical Oncology
Expertise in
11
conditions
Dr. Patricia A. Limpert
Surgical Oncology
Referral may be required

Pink Ribbon Reflections LLC

851 E 5th St Ste 108, 
Washington, MO 
 (43.0 miles away)
636-861-7870
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patricia Limpert is a Surgical Oncologist practicing medicine in Washington, Missouri. She has been practicing medicine for over 17 years. Dr. Limpert is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Intraductal Papilloma, Breast Cancer, Paget Disease of the Breast, Galactocoele, and Lymphadenectomy. Dr. Limpert is currently accepting new patients.

Expertise in
7
conditions
Dr. Tonya M. Martin-Dunlap
Surgical Oncology
Expertise in
7
conditions
Dr. Tonya M. Martin-Dunlap
Surgical Oncology
Referral may be required

Office

232 S Woods Mill Rd Ste 200, 
Chesterfield, MO 
 (14.6 miles away)
314-205-6491
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tonya Martin-Dunlap is a Surgical Oncologist practicing medicine in Chesterfield, Missouri. Dr. Martin-Dunlap is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Martin-Dunlap is currently accepting new patients.

Frequently Asked Questions about Dr. Chet W. Hammill

How do I make an appointment with Dr. Chet W. Hammill?

You can book an appointment with Dr. Chet W. Hammill by calling their office at 314-273-1809. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Chet W. Hammill a top-rated expert for Pancreaticoduodenectomy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Chet W. Hammill is classified as an Distinguished expert for Pancreaticoduodenectomy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Chet W. Hammill specialize in?

While Dr. Chet W. Hammill is a Surgical Oncology, they have specific expertise in Pancreaticoduodenectomy, Gallbladder Removal, and Pancreatectomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Chet W. Hammill participate in research or clinical trials?

Yes. Dr. Chet W. Hammill has published 88 articles and abstracts on conditions like Pancreaticoduodenectomy. You can view a list of Dr. Chet W. Hammill's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Chet W. Hammill accept my insurance?

Dr. Chet W. Hammill accepts most major insurance plans, including BridgeSpan and Cigna. We recommend calling the office directly at 314-273-1809 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hammill's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile